CPHI South East Asia 2025
July 16-18, 2025
Kuala Lumpur, Malaysia
https://www.cphi.com/sea/en/home.html
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Upcoming
Events
CPHI 2025
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
BIO-Europe 2025
November 3-5, 2025
Vienna, Austria
https://informaconnect.com/bioeurope/
Past
Events
Archive
Pharmapack
January 24-25, 2024 Paris, France https://www.pharmapackeurope.com/
read morePharmasynergy
February 08-09, 2024
London, UK
euroPLX84
February 26-27, 2024 Lisbon, Portugal
read moreBIO-Europe Spring
March 18-20, 2024
Barcelona, Spain
https://informaconnect.com/bioeurope-spring/
4th Wet AMD & Diabetic Eye Disease Drug Development
March 19-21, 2024
Boston, MA
https://wet-amd-drug-development.com/
BIO International Convention
June 03-06, 2024
San Diego, California
https://www.bio.org/events/bio-international-convention
CPHI South East Asia
July 10-12, 2024 Bangkok, Thailand https://www.cphi.com/sea/en/home.html
read moreCPHI 2024
October 08-10, 2024 Milan, Italy https://www.cphi.com/europe/en/home.html
read morePODD – Partnership Opportunities in Drug Delivery
October 28-29, 2024 Boston, USA https://poddconference.com
read moreBIO-Europe
November 04-06, 2024 Stockholm, Sweden https://informaconnect.com/bioeurope/
read morePharmaSynergyRx 2025
February 27-28, 2025
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2025/
BIO-Europe Spring
March 17-19, 2025
Milan, Italy
https://informaconnect.com/bioeurope-spring/
DCAT Week 2025
March 17-20, 2025
New York City, USA
https://dcatweek.org/
AT Uro Congress
May 22-24, 2025
Vienna, Austria
EuroPLX
June 2-3, 2025
Lisbon, Portugal
Latest
News
Specialty pharmaceutical company AMW takes big steps
Warngau – AMW GmbH, founded in 2008 and based in Warngau south of Munich, is a dynamically growing specialist pharmaceutical company with bright prospects. The company develops and distributes transdermal systems, i.e. active ingredients that enter the body through the skin, as well as implants loaded with highly effective active ingredients, which release their active ingredient evenly to the body for months and dissolve completely. AMW is supported by well-known investors. In a recent financing round to finance growth, investors reaffirmed their commitment to AMW and contributed a further six million euros.
read moreChamber of Commerce Munich and Upper Bavaria: Training company 2016
This company ensures qualitythrough vocational training in several occupations.
read moreFor the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.
The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.
read moreBfArM approvals from DCP procedure for Rivastigmin patches granted for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic
On 28 August 2015, the BfArM granted approvals from DCP procedures for rivastigmin patches at doses 4.6 mg/24 h and 9.5 mg/24 h for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic.
read moreSuccessful financing round for pharmaceutical company AMW
AMW GmbH (Arzneimittelwerk Warngau) has received follow-on financing to advance the development and commercialization process for its drug delivery systems. Together with BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM-Fonds and IBG Beteiligungsgesellschaft, the existing investors are putting in a total of up to seven million euros. The funds will be used for the marketing of the existing product portfolio and the development of a new technology for the controlled release of pharmaceuticals. AMW GmbH produces active ingredient implants as well as transdermal systems in the fast-growing fields of oncology, pain therapy and neurology.
read more